Sensei Biotherapeutics is developing a pipeline of investigational medicines that work by “awakening” the immune system to defend and defeat cancer and infectious diseases. Sensei’s most advanced ImmunoPhage™ program is SNS-301, a therapy that targets Aspartyl beta Hydroxylase (ASPH) in a Phase 1/2 study of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). ASPH is overexpressed in many types of cancer, including both hematologic and solid tumors.
in combination with pembrolizumab
- PD-1 blockade has been approved for several years in the treatment of advanced SCCHN after platinum-containing chemotherapy, but the objective response rate has been reported to be modest at 13% to 18% with progression-free survival (PFS) of two months and overall survival (OS) of eight months.
- The addition of SNS-301 has the potential to enhance PD-1 blockade activity.
- We also intend to use an ImmunoPhage cocktail targeting the E6/E7 antigens of HPV, in combination with SNS-301, in HPV-positive patients in our ongoing trial of SNS-301.
evaluating combination strategies
- First custom MCC vaccine consisting of Merkel Cell Polyoma Virus (MCPyV) epitopes together with other patient-specific antigens.
- MCC is a rare but highly aggressive neuroendocrine carcinoma of the skin in which MCPyV infection and chronic exposure to ultraviolet radiation are key risk factors.
- Although systemic PD-1/PD-L1 inhibition therapy is associated with a high overall response rate, prolonged durable responses, and good tolerability in advanced-stage MCC, refractory PD-1/PD-L1 inhibitor disease remains a significant unmet medical need with an aggressive clinical course.
- VISTA is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils, monocytes, macrophages, basophils, and dendritic cells.
- VISTA blockade appears to dramatically modulate the tumor microenvironment toward a state that favors an immune system response, resulting in improved T cell effector function and anti-tumor activity.
- Proprietary nanobodies, derived from alpacas, are antibody-like structures that consist of a single monomeric variable domain located on the heavy chain.
- We are developing nanobodies targeted to immune checkpoints and other immune-stimulatory molecules that can be packaged into the phage as immunomodulatory payloads to enhance immunogenicity.